[Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2)].
Identifieur interne : 000525 ( Ncbi/Merge ); précédent : 000524; suivant : 000526[Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2)].
Auteurs : N A Mazurkova ; N N Ryndiuk ; L N Shishkina ; V A Ternovo ; Iu V. Tumanov ; L E Bulychev ; M O Skarnovich ; A S Kabanov ; S G Panchenko ; R P Ale Nikov ; T N Il'Ina ; V I Kuzubov ; S Ia Mel'Nikov ; A N Mironov ; S A Korovkin ; A N Sergeev ; I G DrozdovSource :
- Vestnik Rossiiskoi akademii meditsinskikh nauk [ 0869-6047 ] ; 2010.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Rappel de vaccin, Sous-type H5N1 du virus de la grippe A (immunologie), Sous-type H5N2 du virus de la grippe A (immunologie), Vaccination, Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Virus recombinants (immunologie).
- MESH :
- effets indésirables : Vaccins antigrippaux.
- immunologie : Sous-type H5N1 du virus de la grippe A, Sous-type H5N2 du virus de la grippe A, Vaccins antigrippaux, Virus recombinants.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Rappel de vaccin, Vaccination.
English descriptors
- KwdEn :
- Adolescent, Adult, Female, Humans, Immunization, Secondary, Influenza A Virus, H5N1 Subtype (immunology), Influenza A Virus, H5N2 Subtype (immunology), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Male, Middle Aged, Reassortant Viruses (immunology), Vaccination, Young Adult.
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- immunology : Influenza A Virus, H5N1 Subtype, Influenza A Virus, H5N2 Subtype, Influenza Vaccines, Reassortant Viruses.
- Adolescent, Adult, Female, Humans, Immunization, Secondary, Male, Middle Aged, Vaccination, Young Adult.
Abstract
Results of phase II of a clinical trial of the influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2) are presented. The vaccine was developed based on strain /17/Duck/Potsdam/86/92 H5N2 [17/H5] - reassortant of two viruses, /Leningrad/134/17/57 (H2N2) and /Duck/Potsdam/1402-86 (H5N2), obtained from the Virology Department, St. Petersburg Institute of Experimental Medicine.Two schemes of immunization (with revaccination on days 10 and 21) were used. Evaluation of vaccine immunogenicity included determination of local, cellular and humoral immunity. A significant rise in the level of secretory IgA in the nasal cavity of vaccinated volunteers (with revaccination on days 10 and 21) was documented after application of the vaccine. The postvaccination humoral immune response was estimated from the level of significant (4-fold and more) antibody seroconversions, geometric mean titers of antibodies to two strains of influenza virus /17/Duck/Potsdam/86/92 H5N2 [17/H5] and /Chicken/Suzdalka/Nov-11/2005 (H5N1), and their incremental rate. Results of measurement of antibody titers in hemagglutination-inhibition assay are presented, with two antigens being used to analyse all serum samples from volunteers twice vaccinated with influenza vaccine "Ultragrivac" at 10 and 21 day intervals. Result of phase II of this clinical study show that influenza allantoic intranasal live vaccine "Ultragrivac" is nonreactogenic and safe for both vaccinated and surrounding individuals. Moreover, it is sufficiently immunogenic with respect not only to homologous virus A(H5N2) but also to the A(H5N1) strain.
PubMed: 20422755
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000200
- to stream PubMed, to step Curation: 000200
- to stream PubMed, to step Checkpoint: 000168
Links to Exploration step
pubmed:20422755Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2)].</title>
<author><name sortKey="Mazurkova, N A" sort="Mazurkova, N A" uniqKey="Mazurkova N" first="N A" last="Mazurkova">N A Mazurkova</name>
</author>
<author><name sortKey="Ryndiuk, N N" sort="Ryndiuk, N N" uniqKey="Ryndiuk N" first="N N" last="Ryndiuk">N N Ryndiuk</name>
</author>
<author><name sortKey="Shishkina, L N" sort="Shishkina, L N" uniqKey="Shishkina L" first="L N" last="Shishkina">L N Shishkina</name>
</author>
<author><name sortKey="Ternovo, V A" sort="Ternovo, V A" uniqKey="Ternovo V" first="V A" last="Ternovo">V A Ternovo</name>
</author>
<author><name sortKey="Tumanov, Iu V" sort="Tumanov, Iu V" uniqKey="Tumanov I" first="Iu V" last="Tumanov">Iu V. Tumanov</name>
</author>
<author><name sortKey="Bulychev, L E" sort="Bulychev, L E" uniqKey="Bulychev L" first="L E" last="Bulychev">L E Bulychev</name>
</author>
<author><name sortKey="Skarnovich, M O" sort="Skarnovich, M O" uniqKey="Skarnovich M" first="M O" last="Skarnovich">M O Skarnovich</name>
</author>
<author><name sortKey="Kabanov, A S" sort="Kabanov, A S" uniqKey="Kabanov A" first="A S" last="Kabanov">A S Kabanov</name>
</author>
<author><name sortKey="Panchenko, S G" sort="Panchenko, S G" uniqKey="Panchenko S" first="S G" last="Panchenko">S G Panchenko</name>
</author>
<author><name sortKey="Ale Nikov, R P" sort="Ale Nikov, R P" uniqKey="Ale Nikov R" first="R P" last="Ale Nikov">R P Ale Nikov</name>
</author>
<author><name sortKey="Il Ina, T N" sort="Il Ina, T N" uniqKey="Il Ina T" first="T N" last="Il'Ina">T N Il'Ina</name>
</author>
<author><name sortKey="Kuzubov, V I" sort="Kuzubov, V I" uniqKey="Kuzubov V" first="V I" last="Kuzubov">V I Kuzubov</name>
</author>
<author><name sortKey="Mel Nikov, S Ia" sort="Mel Nikov, S Ia" uniqKey="Mel Nikov S" first="S Ia" last="Mel'Nikov">S Ia Mel'Nikov</name>
</author>
<author><name sortKey="Mironov, A N" sort="Mironov, A N" uniqKey="Mironov A" first="A N" last="Mironov">A N Mironov</name>
</author>
<author><name sortKey="Korovkin, S A" sort="Korovkin, S A" uniqKey="Korovkin S" first="S A" last="Korovkin">S A Korovkin</name>
</author>
<author><name sortKey="Sergeev, A N" sort="Sergeev, A N" uniqKey="Sergeev A" first="A N" last="Sergeev">A N Sergeev</name>
</author>
<author><name sortKey="Drozdov, I G" sort="Drozdov, I G" uniqKey="Drozdov I" first="I G" last="Drozdov">I G Drozdov</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20422755</idno>
<idno type="pmid">20422755</idno>
<idno type="wicri:Area/PubMed/Corpus">000200</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000200</idno>
<idno type="wicri:Area/PubMed/Curation">000200</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000200</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000168</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000168</idno>
<idno type="wicri:Area/Ncbi/Merge">000525</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2)].</title>
<author><name sortKey="Mazurkova, N A" sort="Mazurkova, N A" uniqKey="Mazurkova N" first="N A" last="Mazurkova">N A Mazurkova</name>
</author>
<author><name sortKey="Ryndiuk, N N" sort="Ryndiuk, N N" uniqKey="Ryndiuk N" first="N N" last="Ryndiuk">N N Ryndiuk</name>
</author>
<author><name sortKey="Shishkina, L N" sort="Shishkina, L N" uniqKey="Shishkina L" first="L N" last="Shishkina">L N Shishkina</name>
</author>
<author><name sortKey="Ternovo, V A" sort="Ternovo, V A" uniqKey="Ternovo V" first="V A" last="Ternovo">V A Ternovo</name>
</author>
<author><name sortKey="Tumanov, Iu V" sort="Tumanov, Iu V" uniqKey="Tumanov I" first="Iu V" last="Tumanov">Iu V. Tumanov</name>
</author>
<author><name sortKey="Bulychev, L E" sort="Bulychev, L E" uniqKey="Bulychev L" first="L E" last="Bulychev">L E Bulychev</name>
</author>
<author><name sortKey="Skarnovich, M O" sort="Skarnovich, M O" uniqKey="Skarnovich M" first="M O" last="Skarnovich">M O Skarnovich</name>
</author>
<author><name sortKey="Kabanov, A S" sort="Kabanov, A S" uniqKey="Kabanov A" first="A S" last="Kabanov">A S Kabanov</name>
</author>
<author><name sortKey="Panchenko, S G" sort="Panchenko, S G" uniqKey="Panchenko S" first="S G" last="Panchenko">S G Panchenko</name>
</author>
<author><name sortKey="Ale Nikov, R P" sort="Ale Nikov, R P" uniqKey="Ale Nikov R" first="R P" last="Ale Nikov">R P Ale Nikov</name>
</author>
<author><name sortKey="Il Ina, T N" sort="Il Ina, T N" uniqKey="Il Ina T" first="T N" last="Il'Ina">T N Il'Ina</name>
</author>
<author><name sortKey="Kuzubov, V I" sort="Kuzubov, V I" uniqKey="Kuzubov V" first="V I" last="Kuzubov">V I Kuzubov</name>
</author>
<author><name sortKey="Mel Nikov, S Ia" sort="Mel Nikov, S Ia" uniqKey="Mel Nikov S" first="S Ia" last="Mel'Nikov">S Ia Mel'Nikov</name>
</author>
<author><name sortKey="Mironov, A N" sort="Mironov, A N" uniqKey="Mironov A" first="A N" last="Mironov">A N Mironov</name>
</author>
<author><name sortKey="Korovkin, S A" sort="Korovkin, S A" uniqKey="Korovkin S" first="S A" last="Korovkin">S A Korovkin</name>
</author>
<author><name sortKey="Sergeev, A N" sort="Sergeev, A N" uniqKey="Sergeev A" first="A N" last="Sergeev">A N Sergeev</name>
</author>
<author><name sortKey="Drozdov, I G" sort="Drozdov, I G" uniqKey="Drozdov I" first="I G" last="Drozdov">I G Drozdov</name>
</author>
</analytic>
<series><title level="j">Vestnik Rossiiskoi akademii meditsinskikh nauk</title>
<idno type="ISSN">0869-6047</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization, Secondary</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Influenza A Virus, H5N2 Subtype (immunology)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Reassortant Viruses (immunology)</term>
<term>Vaccination</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Rappel de vaccin</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H5N2 du virus de la grippe A (immunologie)</term>
<term>Vaccination</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Virus recombinants (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term>
<term>Sous-type H5N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Virus recombinants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
<term>Influenza A Virus, H5N2 Subtype</term>
<term>Influenza Vaccines</term>
<term>Reassortant Viruses</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization, Secondary</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Vaccination</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Rappel de vaccin</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Results of phase II of a clinical trial of the influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2) are presented. The vaccine was developed based on strain /17/Duck/Potsdam/86/92 H5N2 [17/H5] - reassortant of two viruses, /Leningrad/134/17/57 (H2N2) and /Duck/Potsdam/1402-86 (H5N2), obtained from the Virology Department, St. Petersburg Institute of Experimental Medicine.Two schemes of immunization (with revaccination on days 10 and 21) were used. Evaluation of vaccine immunogenicity included determination of local, cellular and humoral immunity. A significant rise in the level of secretory IgA in the nasal cavity of vaccinated volunteers (with revaccination on days 10 and 21) was documented after application of the vaccine. The postvaccination humoral immune response was estimated from the level of significant (4-fold and more) antibody seroconversions, geometric mean titers of antibodies to two strains of influenza virus /17/Duck/Potsdam/86/92 H5N2 [17/H5] and /Chicken/Suzdalka/Nov-11/2005 (H5N1), and their incremental rate. Results of measurement of antibody titers in hemagglutination-inhibition assay are presented, with two antigens being used to analyse all serum samples from volunteers twice vaccinated with influenza vaccine "Ultragrivac" at 10 and 21 day intervals. Result of phase II of this clinical study show that influenza allantoic intranasal live vaccine "Ultragrivac" is nonreactogenic and safe for both vaccinated and surrounding individuals. Moreover, it is sufficiently immunogenic with respect not only to homologous virus A(H5N2) but also to the A(H5N1) strain.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20422755</PMID>
<DateCompleted><Year>2010</Year>
<Month>06</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>10</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0869-6047</ISSN>
<JournalIssue CitedMedium="Print"><Issue>3</Issue>
<PubDate><Year>2010</Year>
</PubDate>
</JournalIssue>
<Title>Vestnik Rossiiskoi akademii meditsinskikh nauk</Title>
<ISOAbbreviation>Vestn. Akad. Med. Nauk SSSR</ISOAbbreviation>
</Journal>
<ArticleTitle>[Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2)].</ArticleTitle>
<Pagination><MedlinePgn>15-20</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Results of phase II of a clinical trial of the influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2) are presented. The vaccine was developed based on strain /17/Duck/Potsdam/86/92 H5N2 [17/H5] - reassortant of two viruses, /Leningrad/134/17/57 (H2N2) and /Duck/Potsdam/1402-86 (H5N2), obtained from the Virology Department, St. Petersburg Institute of Experimental Medicine.Two schemes of immunization (with revaccination on days 10 and 21) were used. Evaluation of vaccine immunogenicity included determination of local, cellular and humoral immunity. A significant rise in the level of secretory IgA in the nasal cavity of vaccinated volunteers (with revaccination on days 10 and 21) was documented after application of the vaccine. The postvaccination humoral immune response was estimated from the level of significant (4-fold and more) antibody seroconversions, geometric mean titers of antibodies to two strains of influenza virus /17/Duck/Potsdam/86/92 H5N2 [17/H5] and /Chicken/Suzdalka/Nov-11/2005 (H5N1), and their incremental rate. Results of measurement of antibody titers in hemagglutination-inhibition assay are presented, with two antigens being used to analyse all serum samples from volunteers twice vaccinated with influenza vaccine "Ultragrivac" at 10 and 21 day intervals. Result of phase II of this clinical study show that influenza allantoic intranasal live vaccine "Ultragrivac" is nonreactogenic and safe for both vaccinated and surrounding individuals. Moreover, it is sufficiently immunogenic with respect not only to homologous virus A(H5N2) but also to the A(H5N1) strain.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazurkova</LastName>
<ForeName>N A</ForeName>
<Initials>NA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ryndiuk</LastName>
<ForeName>N N</ForeName>
<Initials>NN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shishkina</LastName>
<ForeName>L N</ForeName>
<Initials>LN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ternovoĭ</LastName>
<ForeName>V A</ForeName>
<Initials>VA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tumanov</LastName>
<ForeName>Iu V</ForeName>
<Initials>IuV</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bulychev</LastName>
<ForeName>L E</ForeName>
<Initials>LE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Skarnovich</LastName>
<ForeName>M O</ForeName>
<Initials>MO</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kabanov</LastName>
<ForeName>A S</ForeName>
<Initials>AS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Panchenko</LastName>
<ForeName>S G</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Aleĭnikov</LastName>
<ForeName>R P</ForeName>
<Initials>RP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Il'ina</LastName>
<ForeName>T N</ForeName>
<Initials>TN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kuzubov</LastName>
<ForeName>V I</ForeName>
<Initials>VI</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mel'nikov</LastName>
<ForeName>S Ia</ForeName>
<Initials>SIa</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mironov</LastName>
<ForeName>A N</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Korovkin</LastName>
<ForeName>S A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sergeev</LastName>
<ForeName>A N</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Drozdov</LastName>
<ForeName>I G</ForeName>
<Initials>IG</Initials>
</Author>
</AuthorList>
<Language>rus</Language>
<PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Russia (Federation)</Country>
<MedlineTA>Vestn Ross Akad Med Nauk</MedlineTA>
<NlmUniqueID>9215641</NlmUniqueID>
<ISSNLinking>0869-6047</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053125" MajorTopicYN="N">Influenza A Virus, H5N2 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016865" MajorTopicYN="N">Reassortant Viruses</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>6</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20422755</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Ale Nikov, R P" sort="Ale Nikov, R P" uniqKey="Ale Nikov R" first="R P" last="Ale Nikov">R P Ale Nikov</name>
<name sortKey="Bulychev, L E" sort="Bulychev, L E" uniqKey="Bulychev L" first="L E" last="Bulychev">L E Bulychev</name>
<name sortKey="Drozdov, I G" sort="Drozdov, I G" uniqKey="Drozdov I" first="I G" last="Drozdov">I G Drozdov</name>
<name sortKey="Il Ina, T N" sort="Il Ina, T N" uniqKey="Il Ina T" first="T N" last="Il'Ina">T N Il'Ina</name>
<name sortKey="Kabanov, A S" sort="Kabanov, A S" uniqKey="Kabanov A" first="A S" last="Kabanov">A S Kabanov</name>
<name sortKey="Korovkin, S A" sort="Korovkin, S A" uniqKey="Korovkin S" first="S A" last="Korovkin">S A Korovkin</name>
<name sortKey="Kuzubov, V I" sort="Kuzubov, V I" uniqKey="Kuzubov V" first="V I" last="Kuzubov">V I Kuzubov</name>
<name sortKey="Mazurkova, N A" sort="Mazurkova, N A" uniqKey="Mazurkova N" first="N A" last="Mazurkova">N A Mazurkova</name>
<name sortKey="Mel Nikov, S Ia" sort="Mel Nikov, S Ia" uniqKey="Mel Nikov S" first="S Ia" last="Mel'Nikov">S Ia Mel'Nikov</name>
<name sortKey="Mironov, A N" sort="Mironov, A N" uniqKey="Mironov A" first="A N" last="Mironov">A N Mironov</name>
<name sortKey="Panchenko, S G" sort="Panchenko, S G" uniqKey="Panchenko S" first="S G" last="Panchenko">S G Panchenko</name>
<name sortKey="Ryndiuk, N N" sort="Ryndiuk, N N" uniqKey="Ryndiuk N" first="N N" last="Ryndiuk">N N Ryndiuk</name>
<name sortKey="Sergeev, A N" sort="Sergeev, A N" uniqKey="Sergeev A" first="A N" last="Sergeev">A N Sergeev</name>
<name sortKey="Shishkina, L N" sort="Shishkina, L N" uniqKey="Shishkina L" first="L N" last="Shishkina">L N Shishkina</name>
<name sortKey="Skarnovich, M O" sort="Skarnovich, M O" uniqKey="Skarnovich M" first="M O" last="Skarnovich">M O Skarnovich</name>
<name sortKey="Ternovo, V A" sort="Ternovo, V A" uniqKey="Ternovo V" first="V A" last="Ternovo">V A Ternovo</name>
<name sortKey="Tumanov, Iu V" sort="Tumanov, Iu V" uniqKey="Tumanov I" first="Iu V" last="Tumanov">Iu V. Tumanov</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000525 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000525 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:20422755 |texte= [Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine "Ultragrivac" (type A/H5N2)]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:20422755" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |